title: Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
authors.affiliation: University Hospital Heidelberg, Germany maximilian.merz@med.uni-heidelberg.de.
authors.forename: Maximilian
authors.initials: M
authors.lastname: Merz
authors.affiliation: Asklepios Hospital Hamburg Altona, Germany.
authors.forename: Hans
authors.initials: H
authors.lastname: Salwender
authors.affiliation: Klinikum Chemnitz, Germany.
authors.forename: Mathias
authors.initials: M
authors.lastname: Haenel
authors.affiliation: University Hospital Heidelberg, Germany.
authors.forename: Elias K
authors.initials: EK
authors.lastname: Mai
authors.affiliation: University Hospital Heidelberg, Germany.|National Center for Tumor Diseases Heidelberg, Germany.
authors.forename: Uta
authors.initials: U
authors.lastname: Bertsch
authors.affiliation: German Cancer Research Center Heidelberg, Germany.
authors.forename: Christina
authors.initials: C
authors.lastname: Kunz
authors.affiliation: German Cancer Research Center Heidelberg, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Hielscher
authors.affiliation: Charité Universitätsmedizin Berlin, Germany.
authors.forename: Igor W
authors.initials: IW
authors.lastname: Blau
authors.affiliation: University Hospital Cologne, Germany.
authors.forename: Christof
authors.initials: C
authors.lastname: Scheid
authors.affiliation: University Hospital Heidelberg, Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Hose
authors.affiliation: University Hospital Heidelberg, Germany.
authors.forename: Anja
authors.initials: A
authors.lastname: Seckinger
authors.affiliation: Institute of Human Genetics, University of Heidelberg, Germany.
authors.forename: Anna
authors.initials: A
authors.lastname: Jauch
authors.affiliation: University Hospital Heidelberg, Germany.
authors.forename: Jens
authors.initials: J
authors.lastname: Hillengass
authors.affiliation: University Hospital Heidelberg, Germany.
authors.forename: Marc S
authors.initials: MS
authors.lastname: Raab
authors.affiliation: University Hospital Heidelberg, Germany.
authors.forename: Baerbel
authors.initials: B
authors.lastname: Schurich
authors.affiliation: University Medical Center Mainz, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Munder
authors.affiliation: University Hospital Bonn, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Brossart
authors.affiliation: Helios Hospital Berlin Buch, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Gerecke
authors.affiliation: Kath. Krankenhaus Hagen, Germany.
authors.forename: Hans-Walter
authors.initials: HW
authors.lastname: Lindemann
authors.affiliation: Asklepios Hospital St. Georg Hamburgy, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Zeis
authors.affiliation: University Hospital Tübingen, Germany.
authors.forename: Katja
authors.initials: K
authors.lastname: Weisel
authors.affiliation: University Hospital Essen, Germany.
authors.forename: Jan
authors.initials: J
authors.lastname: Duerig
authors.affiliation: University Hospital Heidelberg, Germany.|National Center for Tumor Diseases Heidelberg, Germany.
authors.forename: Hartmut
authors.initials: H
authors.lastname: Goldschmidt
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000069286:Bortezomib / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D060828:Induction Chemotherapy / Q000009:adverse effects / Q000379:methods; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D000069286:Bortezomib